Cargando…

58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)

BACKGROUND: LC is a late and often fatal manifestation of advanced EGFR mutated NSCLC with up to 9% of patients developing LC. Given the higher incidence of LC in EGFR mutated tumors, we hypothesized it may have unique imaging and clinical characteristics. METHODS: We identified 23 patients with EGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Eastman, Boryana, Merkhofer, Cristina, Densmore, Isabella, Baik, Christina, Halasz, Lia, McGranahan, Tresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401415/
http://dx.doi.org/10.1093/noajnl/vdaa073.046
_version_ 1783566559599394816
author Eastman, Boryana
Merkhofer, Cristina
Densmore, Isabella
Baik, Christina
Halasz, Lia
McGranahan, Tresa
author_facet Eastman, Boryana
Merkhofer, Cristina
Densmore, Isabella
Baik, Christina
Halasz, Lia
McGranahan, Tresa
author_sort Eastman, Boryana
collection PubMed
description BACKGROUND: LC is a late and often fatal manifestation of advanced EGFR mutated NSCLC with up to 9% of patients developing LC. Given the higher incidence of LC in EGFR mutated tumors, we hypothesized it may have unique imaging and clinical characteristics. METHODS: We identified 23 patients with EGFR mutated NSCLC and LC treated at a large academic institution between 2016 and 2019. Clinical and treatment characteristics were obtained from the electronic medical record. Radiographic subtype of LC and presence of ventriculomegaly were determined by independent review of available brain and spine MRI imaging. RESULTS: Among 23 eligible patients, mean age was 57 years, 96% had advanced NSCLC at diagnosis and 61% had EGFR exon 19 deletion. Median time from NSCLC diagnosis to LC development was 23 months (95% CI:13–33), with only 17% of patients presenting with LC in the absence of parenchymal brain metastases. Of the 91% of patients with radiographic evidence of LC, equal numbers had nodular or linear LC (22% each) and 39% had a mixed presentation. Additionally, 30% of patients had evidence of spinal LC. Ventriculomegaly was present in 52% of patients, with 48% developing clinical symptoms of hydrocephalus and 13% receiving shunt placement. Median overall survival (OS) from time of LC diagnosis was 3.9 months (95% CI:2.7–10.0), which is lower than in prior published studies. Patients with nodular LC and absence of ventriculomegaly fared better with a median OS of 6.5 months and 5.7 months respectively. CONCLUSIONS: OS is poor in patients with LC associated with EGFR mutated NSCLC, although appears better in patients with nodular LC. The high incidence of hydrocephalus emphasizes the need for its early recognition and treatment. Further studies are needed to identify promising treatment strategies and to determine factors associated with improved OS in this population.
format Online
Article
Text
id pubmed-7401415
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-74014152020-08-06 58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC) Eastman, Boryana Merkhofer, Cristina Densmore, Isabella Baik, Christina Halasz, Lia McGranahan, Tresa Neurooncol Adv Supplement Abstracts BACKGROUND: LC is a late and often fatal manifestation of advanced EGFR mutated NSCLC with up to 9% of patients developing LC. Given the higher incidence of LC in EGFR mutated tumors, we hypothesized it may have unique imaging and clinical characteristics. METHODS: We identified 23 patients with EGFR mutated NSCLC and LC treated at a large academic institution between 2016 and 2019. Clinical and treatment characteristics were obtained from the electronic medical record. Radiographic subtype of LC and presence of ventriculomegaly were determined by independent review of available brain and spine MRI imaging. RESULTS: Among 23 eligible patients, mean age was 57 years, 96% had advanced NSCLC at diagnosis and 61% had EGFR exon 19 deletion. Median time from NSCLC diagnosis to LC development was 23 months (95% CI:13–33), with only 17% of patients presenting with LC in the absence of parenchymal brain metastases. Of the 91% of patients with radiographic evidence of LC, equal numbers had nodular or linear LC (22% each) and 39% had a mixed presentation. Additionally, 30% of patients had evidence of spinal LC. Ventriculomegaly was present in 52% of patients, with 48% developing clinical symptoms of hydrocephalus and 13% receiving shunt placement. Median overall survival (OS) from time of LC diagnosis was 3.9 months (95% CI:2.7–10.0), which is lower than in prior published studies. Patients with nodular LC and absence of ventriculomegaly fared better with a median OS of 6.5 months and 5.7 months respectively. CONCLUSIONS: OS is poor in patients with LC associated with EGFR mutated NSCLC, although appears better in patients with nodular LC. The high incidence of hydrocephalus emphasizes the need for its early recognition and treatment. Further studies are needed to identify promising treatment strategies and to determine factors associated with improved OS in this population. Oxford University Press 2020-08-04 /pmc/articles/PMC7401415/ http://dx.doi.org/10.1093/noajnl/vdaa073.046 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Eastman, Boryana
Merkhofer, Cristina
Densmore, Isabella
Baik, Christina
Halasz, Lia
McGranahan, Tresa
58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
title 58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
title_full 58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
title_fullStr 58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
title_full_unstemmed 58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
title_short 58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
title_sort 58. clinical presentation and imaging characteristics of leptomeningeal carcinomatosis (lc) in patients with egfr mutated non-small cell lung cancer (nsclc)
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401415/
http://dx.doi.org/10.1093/noajnl/vdaa073.046
work_keys_str_mv AT eastmanboryana 58clinicalpresentationandimagingcharacteristicsofleptomeningealcarcinomatosislcinpatientswithegfrmutatednonsmallcelllungcancernsclc
AT merkhofercristina 58clinicalpresentationandimagingcharacteristicsofleptomeningealcarcinomatosislcinpatientswithegfrmutatednonsmallcelllungcancernsclc
AT densmoreisabella 58clinicalpresentationandimagingcharacteristicsofleptomeningealcarcinomatosislcinpatientswithegfrmutatednonsmallcelllungcancernsclc
AT baikchristina 58clinicalpresentationandimagingcharacteristicsofleptomeningealcarcinomatosislcinpatientswithegfrmutatednonsmallcelllungcancernsclc
AT halaszlia 58clinicalpresentationandimagingcharacteristicsofleptomeningealcarcinomatosislcinpatientswithegfrmutatednonsmallcelllungcancernsclc
AT mcgranahantresa 58clinicalpresentationandimagingcharacteristicsofleptomeningealcarcinomatosislcinpatientswithegfrmutatednonsmallcelllungcancernsclc